Literature DB >> 17539006

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Fabio Piscaglia1, Valeria Camaggi, Matteo Ravaioli, Gian Luca Grazi, Matteo Zanello, Simona Leoni, Giorgio Ballardini, Giulia Cavrini, Antonio Daniele Pinna, Luigi Bolondi.   

Abstract

The best prioritization of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation under the model for end-stage liver disease (MELD) allocation system is still being debated. We analyzed the impact of a MELD adjustment for HCC, which consisted of the addition of an extra score (based on the HCC stage and waiting time) to the native MELD score. The outcome was analyzed for 301 patients with chronic liver disease listed for liver transplantation between March 1, 2001 and February 28, 2003 [United Network for Organ Sharing (UNOS)-Child-Turcotte-Pugh (CTP) era, 163 patients, 28.8% with HCC] and between March 1, 2003 and February 28, 2004 (HCC-MELD era, 138 patients, 29.7% with HCC). In the HCC-MELD era, the cumulative dropout risk at 6 months was 17.6% for patients with HCC versus 22.3% for those patients without HCC (P = NS), similar to that in the UNOS-CTP era. The cumulative probability of transplantation at 6 months was 70.3% versus 39.0% (P = 0.005), being higher than that in the UNOS-CTP era for patients with HCC (P = 0.02). At the end of the HCC-MELD era, 12 patients with HCC (29.3%) versus 57 without HCC (58.8%) were still on the list (P = 0.001). Both native and adjusted MELD scores were higher (P < 0.05) and progressed more in patients with HCC who dropped out than in those who underwent transplantation or remained on the list (the initial-final native MELD scores were 17.3-23.1, 15.5-15.6, and 12.8-14.1, respectively). The patients without HCC remaining on the list showed stable MELD scores (initial-final: 15.1-15.4). In conclusion, the present data support the strategy of including the native MELD scores in the allocation system for HCC. This model allows the timely transplantation of patients with HCC without severely affecting the outcome of patients without HCC.

Entities:  

Mesh:

Year:  2007        PMID: 17539006     DOI: 10.1002/lt.21155

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

Review 2.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

3.  Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up.

Authors:  M Schmeding; C Heidenhain; R Neuhaus; P Neuhaus; U P Neumann
Journal:  Dig Dis Sci       Date:  2010-05-25       Impact factor: 3.199

4.  TACE performed in patients with a single nodule of hepatocellular carcinoma.

Authors:  Eleonora Terzi; Fabio Piscaglia; Ludovica Forlani; Cristina Mosconi; Matteo Renzulli; Luigi Bolondi; Rita Golfieri
Journal:  BMC Cancer       Date:  2014-08-19       Impact factor: 4.430

Review 5.  Succinct guide to liver transplantation for medical students.

Authors:  Cheng-Maw Ho; Po-Huang Lee; Wing Tung Cheng; Rey-Heng Hu; Yao-Ming Wu; Ming-Chih Ho
Journal:  Ann Med Surg (Lond)       Date:  2016-11-14

6.  Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria.

Authors:  Matteo Ravaioli; Federica Odaldi; Alessandro Cucchetti; Franco Trevisani; Fabio Piscaglia; Vanessa De Pace; Valentina Rosa Bertuzzo; Flavia Neri; Rita Golfieri; Alberta Cappelli; Antonietta D'Errico; Matteo Cescon; Massimo Del Gaudio; Guido Fallani; Antonio Siniscalchi; Maria Cristina Morelli; Francesca Ciccarese; Maria Di Marco; Fabio Farinati; Edoardo Giovanni Giannini; Antonio Daniele Pinna
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

7.  Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma.

Authors:  Anjiya Shaikh; Karthik Goli; Nicole E Rich; Jihane N Benhammou; Saira Khaderi; Ruben Hernaez; Vatche G Agopian; John M Vierling; Donghee Kim; Aijaz Ahmed; John A Goss; Abbas Rana; Fasiha Kanwal; George Cholankeril
Journal:  Transplant Direct       Date:  2022-04-12

8.  Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.

Authors:  Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2016-02-26       Impact factor: 17.425

9.  Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach.

Authors:  Marco Biolato; Giuseppe Marrone; Luca Miele; Antonio Gasbarrini; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.